Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.50 |
| ▸ | FLT1 | P17948 | 2/20 | 0.50 |
| ▸ | FLT4 | P35916 | 2/20 | 0.50 |
| ▸ | BMP4 | P12644 | 1/20 | 0.50 |
| ▸ | ACVR2A | P27037 | 3/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 8/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901971 | 0.89 | KDR (0.49) | KDRFLT1FLT4ACVR2ARET | |
| SCHEMBL12461799 | 0.88 | RET (0.48) | KDRFLT1FLT4BMP4RET | |
| SCHEMBL12461830 | 0.88 | ERN1 (0.47) | ACVR2ATTKRETGAKTGFBR2 | |
| SCHEMBL13509615 | 0.87 | GAK (0.44) | ACVR2ARETGAK | |
| SCHEMBL12461307 | 0.86 | ERN1 (0.48) | ACVR2ARETGAKTGFBR2 | |
| SCHEMBL12461791 | 0.85 | KDR (0.49) | KDRACVR2ARETGAK | |
| SCHEMBL2354668 | 0.84 | RET (0.53) | RET | |
| SCHEMBL1907353 | 0.84 | KDR (0.48) | KDRACVR2ARETGAK | |
| SCHEMBL12461301 | 0.83 | ACVR2A (0.53) | ACVR2ATTKRETTGFBR2 | |
| SCHEMBL12461272 | 0.83 | RET (0.49) | RETGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | claimed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | claimed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | KDR 1534/4885FLT1 2349/4885FLT4 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.